Association between Myeloperoxidase Levels and Risk of Insulin Resistance in Egyptian Obese Women


  • Moushira Zaki Biological Anthropology Department, Medical Research Division, National Research Centre, Giza
  • Walaa Basha Biological Anthropology Department, Medical Research Division, National Research Centre, Giza
  • Hanaa Reyad Biological Anthropology Department, Medical Research Division, National Research Centre, Giza
  • Ramy Mohamed Biological Anthropology Department, Medical Research Division, National Research Centre, Giza
  • Naglaa Hassan Biological Anthropology Department, Medical Research Division, National Research Centre, Giza
  • Shams Kholousi Immunogenetics Department, Human Genetics and Genome Research Division, National Research Centre, Giza



Myeloperoxidase, Insulin resistance, Blood lipids, Obesity, Women


BACKGROUND: Myeloperoxidase (MPO) is an enzyme involved in the pathogenesis of several diseases.

AIM: The current study aimed to investigate serum MPO levels in obese Egyptian women and assess its relation with insulin resistance (IR) and other biochemical risk parameters.

METHODS: The study included 80 obese women and 50 age-and-sex-matched healthy controls. Insulin resistance (IR) was evaluated by the Homeostasis Model Assessment-Insulin Resistance (HOMA-IR).  Serum MPO, fasting glucose, insulin and blood lipids and anthropometry were measured. Obese cases were divided into three groups based on MPO tertiles. ROC analysis was performed to obtain the optimal cut-off values of MPO to predicate IR in obese women.

RESULTS: The mean serum MPO was significantly higher in obese cases than controls. Cases in the highest MPO tertile had higher HOMA-IR, blood lipids and pressure levels compared with those in the lower tertile. The cutoff point of MPO was > 87.8 (ng/mL) and area under curves was 0.82 (p < 0.01) for diagnosis of IR. MPO levels were higher in obese Egyptian women than healthy controls.

CONCLUSION: Elevation of MPO was associated with abnormal metabolic parameters. MPO might be used as an earlier biomarker for IR and metabolic disturbance in obese women.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


von Leitner E-C, Klinke A, Atzler D, Slocum JL, Lund N, Kielstein JT, et al. Pathogenic cycle between the endogenous nitric oxide synthase inhibitor asymmetrical dimethylarginine and the leukocyte-derived hemoprotein myeloperoxidase. Circulation. 2011; 124(24):2735–45. PMid:22082678

Zhang R, Brennan M-L, Shen Z, MacPherson JC, Schmitt D, Molenda CE, et al. Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002; 277(48):46116–22. PMid:12359714

Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006; 40(2):295–302. PMid:16413411

Yubero-Serrano EM, Delgado-Lista J, Pena-Orihuela P, Perez-Martinez P, Fuentes F, Marin C, et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Exp Mol Med. 2013; 45(6):e28. PMid:23788131 PMCid:PMC3701288

Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations. Diabetes. 2003; 52(9):2346–52. PMid:12941775

Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Circulation. 2004; 109(3):433–8. PMid:14744958

Morris AA, Zhao L, Patel RS, Jones DP, Ahmed Y, Stoyanova N, et al. Differences in systemic oxidative stress based on race and the metabolic syndrome: the Morehouse and Emory Team up to Eliminate Health Disparities (META-Health) study. Metab Syndr Relat Disord. 2012; 10(4):252–9. PMid:22385338 PMCid:PMC3449394

Wiersma JJ, Meuwese MC, van Miert JNI, Kastelein A, Tijssen JGP, Piek JJ, et al. Diabetes mellitus type 2 is associated with higher levels of myeloperoxidase. Med Sci Monit. 2008; 14(8):CR406–10. PMid:18667997

Hiernaux J, Tanner JM, Jarman S. Growth and physical studies. Hum Biol A Guid to F methods London IBP, 1969.

Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, Gude F, García F, De Francisco A, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocr Disord. 2013; 13(1):47. PMid:24131857 PMCid:PMC4016563

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7):412–9. PMid:3899825

Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002; 23(5):599–622. PMid:12372842

Brennan M-L, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003; 349(17):1595–604. PMid:14573731

Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol. 2007; 99(10):1364–8. PMid:17493461

Marsche G, Hammer A, Oskolkova O, Kozarsky KF, Sattler W, Malle E. Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J Biol Chem. 2002; 277(35):32172–9. PMid:12070141

Kim JA, Choi YS, Hong JI, Kim SH, Jung HH, Kim SM. Association of metabolic syndrome with white blood cell subtype and red blood cells. Endocr J. 2006; 53(1):133–9. PMid:16543683

Babio N, Ibarrola-Jurado N, Bulló M, Martínez-González MÃ, Wärnberg J, Salaverría I, et al. White blood cell counts as risk markers of developing metabolic syndrome and its components in the PREDIMED study. PLoS One. 2013; 8(3):e58354. PMid:23526980 PMCid:PMC3602299

Galijasevic S, Saed GM, Diamond MP, Abu-Soud HM. Myeloperoxidase up-regulates the catalytic activity of inducible nitric oxide synthase by preventing nitric oxide feedback inhibition. Proc Natl Acad Sci. 2003; 100(25):14766–71. PMid:14657339 PMCid:PMC299800

Liu Y, Wang D, Li D, Sun R, Xia M. Associations of retinol-binding protein 4 with oxidative stress, inflammatory markers, and metabolic syndrome in a middle-aged and elderly Chinese population. Diabetol Metab Syndr. 2014; 6(1):25. PMid:24559154 PMCid:PMC3938900

Pignatelli P, Loffredo L, Martino F, Catasca E, Carnevale R, Zanoni C, et al. Myeloperoxidase overexpression in children with hypercholesterolemia. Atherosclerosis. 2009; 205(1):239–43. PMid:19081093

Vita JA, Brennan M-L, Gokce N, Mann SA, Goormastic M, Shishehbor MH, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation. 2004; 110(9):1134–9. PMid:15326065 PMCid:PMC2718053

Al-Rasadi K, Al-Zakwani I, Zubaid M, Ali A, Bahnacy Y, Sulaiman K, et al. Prevalence, predictors, and impact of low high-density lipoprotein cholesterol on in-hospital outcomes among acute coronary syndrome patients in the Middle East. Open Cardiovasc Med J. 2011; 5(1). PMid:21966331 PMCid:PMC3178900

Onat A, Can G, Yüksel H. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. Turk Kardiyol Dern Ars. 2012; 40(4):368–85. PMid:22951857

Feng RN, Niu YC, Sun XW, Li Q, Zhao C, Wang C, et al. Histidine supplementation improves insulin resistance through suppressed inflammation in obese women with the metabolic syndrome: a randomised controlled trial. Diabetologia. 2013; 56(5):985–94. PMid:23361591

Daniels SR. Complications of obesity in children and adolescents. Int J Obes. 2009; 33(S1):S60. PMid:19363511

Koh Y, Park J, Carter R. Oxidized Low-Density Lipoprotein and Cell Adhesion Molecules Following Exercise Training. Int J Sports Med. 2017; 2017. PMid:29190851

Rocha-Penha L, Bettiol H, Barbieri MA, Cardoso VC, Cavalli RC, Sandrim VC. Myeloperoxidase is not a good biomarker for preeclampsia prediction. Sci Rep. 2017; 7(1):10257. PMid:28860607 PMCid:PMC5579011

Gariballa S, Alkaabi J, Yasin J, Al Essa A. Oxidative damage and associated inflammatory risk factors in obese Emirati women: Body mass index versus waist circumference. Saudi Med J. 2017; 38(9):960. PMid:28889156 PMCid:PMC5654032

Freedman DS, Dietz WH, Tang R, Mensah GA, Bond MG, Urbina EM, et al. The relation of obesity throughout life to carotid intima-media thickness in adulthood: the Bogalusa Heart Study. Int J Obes. 2004; 28(1):159. PMid:14581934

Meuwese MC, Stroes ESG, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007; 50(2):159–65. PMid:17616301



How to Cite

Zaki M, Basha W, Reyad H, Mohamed R, Hassan N, Kholousi S. Association between Myeloperoxidase Levels and Risk of Insulin Resistance in Egyptian Obese Women. Open Access Maced J Med Sci [Internet]. 2018 Apr. 6 [cited 2023 Feb. 4];6(4):629-33. Available from:



B - Clinical Sciences

Most read articles by the same author(s)